COVID-19 Diagnostic Kits and Therapy Market to Reach $13.9 Billion by 2025- Exclusive Report by Meticulous Research®


London, June 19, 2020 (GLOBE NEWSWIRE) -- According to a new market research report COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025, published by Meticulous Research®, COVID-19 diagnostics kits and therapy market to reach $13.9 billion by 2025.

Download Free Sample Report Now @

The healthcare systems globally have been struggling to manage the COVID-19 patient population and the researchers are racing to find a solution to this problem; while on the other hand, the economic impacts are felt across other sectors. Globally, there has been GDP decline, increase in unemployment rates, and increase in inflation rates.

The high transmission rate of coronavirus that lead to rapid increase in COVID-19 cases and deaths world-wide, triggered the rapid growth in diagnostic and treatment needs. However, lack of information on the novel virus such as biological, genetic information, duration of immunity granted in recovered patients, among others, which is vital to develop a safe & effective treatment option, has been a key challenge in achieving a successful solution.

Studies are on-going in two areas, mainly, diagnostics and treatments. The COVID-19 diagnostics is mainly dominated by PCR-based tests and antibody or serological testing. PCR tests are largely being used in early detection of the coronavirus; whereas, antibody tests are more suitable for recovered patients or to check for herd immunities. The diagnostics firms are currently focusing on strengthening manufacturing and distribution capabilities as well as enhancing automation and process refinements.

In terms of treatment options, the industry is focused on developing vaccines, immunotherapy, antiviral, and cell-based therapies, among others. Currently, in circa 205 different therapies and 124 vaccines are under development (as of May 2020). Leading areas of research include antibodies, protein-based vaccines, antiviral, drug repurposes, RNA-based vaccines, non-replicating viral vectors, and cell-based therapies. With regards to development phase, more than 50% of the pipeline is in preclinical stage.

Quick Buy – COVID-19 Diagnostic Kits and Therapy Market Research Report:

Key challenges impacting the success rate for therapy development are lack of information on the virus such as biological, genetic information, duration of immunity granted in recovered patients, among others, which is vital to develop a safe & effective treatment option. In future, industry is expecting to face challenges related to production capacity & distribution. Thus, while vaccine development is on-going, manufacturers are also focusing on increasing production capacities.

Some of the expected potential game changing treatment includes Canakinumab (Ilaris) by Novartis, ACE-Mab by Sorrento Therapeutics, Remdesivir antiviral by Gilead Sciences, and Hydroxychloroquine and chloroquine (HCQ), among others. Further, unique options such as cell-based therapies involving Mesenchymal stem cells or Natural Killer cells and plasma therapies are expected to provide more personalized treatment options. 

With the growing cases of COVID-19 and its impact on the healthcare industry, this report analyses the diagnosis and treatments areas widely. The diagnosis segment is further divided into PCR-based testing and antibody testing; whereas, the treatment area is segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies. Vaccines and anti-virals are the most explored treatment options currently being investigated by researchers worldwide. The study also evaluates product pipeline based on development stage.

Some of the key players engaged in the COVID-19 diagnosis and treatment development include Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), and Takeda Pharmaceuticals Company Ltd (Japan), among others.

To gain more insights into the market with a detailed table of content and figures, click here:

Scope of the Report:

COVID-19 Product Pipeline                      

  • Diagnosis
    • PCR Testing
    • Antibody Testing
  • Treatment
    • Vaccines          
    • Immunotherapy
    • Antiviral
    • Cell-based Therapy
    • Other Therapies                                        

COVID-19: Impact on Healthcare Industry   

  • Diagnostics
    • Rapid Test Kits
    • PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
      • Advantages Offered by PCR Testing in COVID -19 Diagnosis
      • Restraints
      • Key Companies
    • Antibody Testing / Serological Testing
      • Advantages Over Molecular Tests
      • Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
      • Restraints
      • Key Companies
    • Therapies
      • Vaccines
      • Immunotherapies (Antibodies)
      • Monoclonal Antibody
      • T-Cell Therapy
      • Potential Game Changers: Antibodies
        • Ilaris (Canakinumab)
        • Sylvant (Siltuximab)
        • Lenzilumab
        • Ultomiris (Ravulizumab-Cwvz)
        • Tocilizumab
      • Anti-Virals
        • Potential Game Changers
          • Chloroquine and Hydroxychloroquine (HCQ)
          • Remdesivir
        • Cell-Based Therapies
        • Other Therapies
          • Plasma Therapy
          • Devices

COVID-19 Industry Impact Assessment, by Geography        

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Rest of the World (RoW)       

Download Free Sample Report Now @

Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-   

Related Reports:

Infectious Disease Diagnostics Market by Product and Solution (Consumables, System, Software and Services), Technology (Immunodiagnostics, PCR, INAAT), Disease (HIV, HAIS, Influenza), End User (Hospital, Reference Lab, Research) - Global Forecast to 2027

Vaccines Market by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccine, Live Attenuated Vaccine), Valence (Multivalent, Monovalent Vaccines) - Global Forecast to 2027

Influenza Diagnostics Market by Test Type {[Traditional (RIDT, Direct Fluorescent Antibody, Viral Culture, Serology), Molecular [RT-PCR, INAAT (NASBA, LAMP)]}, End User (Hospitals, Laboratories, Academics, Research Institutes) - Global Forecast to 2027

Ventilators Market by Product (Instruments, Accessories), Mobility (Intensive Care, Portable), Interface (Invasive, Non-invasive), Age Group (Adult, Pediatric), Mode (Volume, Pressure, Dual), End User (Hospital, ASCs, Home Care) – Global Forecast to 2027

Point of Care Molecular Diagnostics Market by Product and Solution (Assay, Analyzer, Software, Services), Technology (RT-qPCR, INAAT), Application (Respiratory Diseases, Hospital Acquired Infections, STD), and End User - Global Forecast to 2027

Medical/Hospital Beds Market by Product (Bed, Accessories), Technology (Power, Manual), Type of Care (Curative, Rehabilitation), Healthcare Facilities (Critical, Bariatric, Long-term, Paediatric, Maternal, Home Care) - Global Forecast to 2027

About Meticulous Research®

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details.

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.


Contact Data